Polypoidal choroidal vasculopathy in Caucasian patients with presumed neovascular age-related macular degeneration and poor ranibizumab response.

Br J Ophthalmol · 2014 · PMC3913166 · PMID 24246375

Europe PMC DOI

hedged sentences

0.0800

closest p · 1.6× alpha

0.0800

boldest claim

The sentences

did not quite reach statistical significancep=0.08so close (0.05 < p ≤ 0.1)

Between injections 1 and 8, the mean interval was 13.8±3.9 months for eyes with PCV and 15.7±5.9 months for eyes without PCV, but the between-group difference did not quite reach statistical significance (p=0.08).

also in 679 other papers

an observed trendno p-value reported

Combining verteporfin with ranibizumab resulted in fewer re-treatments with ranibizumab over 5 months compared with ranibizumab monotherapy and also led to an observed trend towards improved BCVA outcomes. 23 Current guidelines developed from a recent roundtable meeting of PCV experts recommend either ICGA-guided verteporfin PDT or verteporfin PDT together with three monthly 0.5 mg ranibizumab intravitreal injections as the initial treatment of juxtafoveal and subfoveal PCV. 20 In the present study, 16 patients received combination therapy with reduced-fluence verteporfin PDT plus ranibizumab after they were diagnosed with PCV.

also in 504 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.